Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

On February 5, 2021, Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 14 new employees, in compliance with NASDAQ Listing Rule 5635(c)(4). These awards included options for a total of 65,980 shares of common stock at an exercise price of $37.44 per share, aligning with the closing price on February 1, 2021. The options have a ten-year term and a four-year vesting schedule, promoting employee retention and aligning interests with shareholder value.

Positive

• Inducement awards could enhance employee retention and performance.
• Options granted at a market-conform exercise price may align employee incentives with shareholder value.

Negative

• None.

BRIDGEWATER, N.J., Feb. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 14 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, the employees received options on February 1, 2021 to purchase an aggregate 65,980 shares of Insmed common stock at an exercise price of $37.44 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The options have a ten-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States and the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
insmed@argotpartners.com 

Media:

Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301220804.html

SOURCE Insmed Incorporated

FAQ

What inducement awards were granted by Insmed on February 5, 2021?

Insmed granted inducement awards to 14 new employees, totaling 65,980 options to purchase shares at an exercise price of $37.44 each.

What is the vesting schedule for Insmed's employee options?

The options vest over four years, with 25% vesting on the first anniversary and 12.5% every six months thereafter.

How long is the term for the options granted by Insmed?

The options have a ten-year term from the date of grant.